Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation by unknown
ORIGINAL ARTICLE
Clinical diagnostics and therapy monitoring in the congenital
disorders of glycosylation
Monique Van Scherpenzeel1,2 & Esther Willems1,2 & Dirk J. Lefeber1,2
Received: 28 August 2015 /Revised: 3 November 2015 /Accepted: 18 November 2015
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Abnormal protein glycosylation is observed in
many common disorders like cancer, inflammation,
Alzheimer’s disease and diabetes. However, the actual use of
this information in clinical diagnostics is still very limited.
Information is usually derived from analysis of total serum
N-glycan profiling methods, whereas the current use of gly-
coprotein biomarkers in the clinical setting is commonly based
on protein levels. It can be envisioned that combining protein
levels and their glycan isoforms would increase specificity for
early diagnosis and therapy monitoring. To establish diagnos-
tic assays, based on the mass spectrometric analysis of
protein-specific glycosylation abnormalities, still many tech-
nical improvements have to be made. In addition, clinical
validation is equally important as well as an understanding
of the genetic and environmental factors that determine
the protein-specific glycosylation abnormalities. Important
lessons can be learned from the group of monogenic dis-
orders in the glycosylation pathway, the Congenital
Disorders of Glycosylation (CDG). Now that more and
more genetic defects are being unraveled, we start to learn
how genetic factors influence glycomics profiles of indi-
vidual and total serum proteins. Although only in its initial
stages, such studies suggest the importance to establish
diagnostic assays for protein-specific glycosylation profil-
ing, and the need to look beyond the single glycoprotein
diagnostic test. Here, we review progress in and lessons
from genetic disease, and review the increasing opportuni-
ties of mass spectrometry to analyze protein glycosylation
in the clinical diagnostic setting. Furthermore, we will
discuss the possibilities to expand current CDG diagnos-
tics and how this can be used to approach glycoprotein
biomarkers for more common diseases.
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Protein glycosylation is a non-template driven, dynamic,
and post-translational modification on top of protein
synthesis. Glycans have important functions in many
biological processes such as protein folding, clearance
and cell-cell interactions. Considering glycosylation to
be the final and top level after DNA and protein syn-
thesis, glycosylation is the most informative level, being
a product of the genome and environmental factors to-
gether. Therefore, the use of glycomics methods to read
this information holds enormous potential for the devel-
opment of unique biomarkers for human diseases. In
several genetic and chronic diseases, like cancer [1–3],
inflammation [4], Alzheimer’s disease [5], diabetes [6,
7] and metabolic disorders [8], glycosylation of proteins
is changed dramatically. Analysis of glycosylation has
the benefit that it provides information about the current
status of the patient, which enables early diagnosis of
disease onset and therapy monitoring.
Still major technological advances have to be made before
glycoprotein biomarkers can be widely used in clinical
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diagnostics. In addition, clinical validation of potential bio-
markers is equally important as well as the knowledge of
how to interpret glycosylation abnormalities in the context
of a certain disease. Important lessons can be learned by a
comparison with a group of well-defined genetic defects, the
Congenital Disorders of Glycosylation (CDG). CDG encom-
passes a group of inherited diseases with abnormal glycan
metabolism. According to current nomenclature [9], they are
divided into four different biochemical groups, comprising
errors in protein N-linked glycosylation, protein O-linked gly-
cosylation, glycolipid and GPI anchor glycosylation, and a
group with defects in multiple glycosylation pathways [10].
Over 100 human genetic disorders have been associated with
abnormal glycosylation [8, 11], of which at least 50 types are
linked to deficient N-glycosylation of serum transferrin, his-
torically referred to as CDG [12]. Because the defective genes
are involved in a variety of functionally diverse metabolic
pathways, the clinical presentation of CDG subtypes is highly
heterogeneous. Clinical phenotypes range frommild to severe
and involve multiple or only single affected organs. Examples
of clinical symptoms include intellectual disability, seizures,
muscle dystrophy, skeletal dysplasia, dysmorphic features,
growth retardation, hematological and endocrine abnormali-
ties, which show the widespread requirement of proper glyco-
sylation for the human system [13, 14]. In line with these
diverse clinical symptoms, diagnosis can be very challenging.
Currently, only transferrin glycosylation analysis is widely
used in clinical diagnostics for CDG.
Advanced mass spectrometry (MS) was introduced in CDG
research to analyze released glycans from serum proteins
[15–17] to gain more detailed insights in the glycan structural
abnormalities. The growing contribution of mass spectrometry
in the diagnosis of CDG is outlined in a recent review by
Sturiale et al. [18]. Intact glycoprotein analysis of transferrin
followed after the rapid development of mass spectrometry
techniques and has now been added to routine diagnosis [19]
and recently to therapy monitoring of CDG [20]. This method
for protein-specific analysis has allowed high-resolution anno-
tation of glycan structures, thereby revealing unique glycosyl-
ation profiles for specific genetic defects. This shows the po-
tential to include mass spectrometry in specialized diagnostic
laboratories and has already improved the diagnostic process
by significantly shortening the time to reach a diagnosis.
It can be predicted that more glycosylation disorders will
be reported in the near future since at least 2 % of the human
genes encodes for proteins involved in glycan biosynthesis
and recognition [8], and 5–10 % for proteins involved in
Golgi homeostasis with a potential indirect effect on glycan
metabolism. In addition, the wide-spread diagnostic applica-
tion of next-generation sequencing is increasing the speed of
CDG gene discovery [21]. The complexity of different glyco-
sylation pathways, and the existence of tissue- and protein-
specific glycosylation, indicates that the current use of
transferrin as diagnostic marker is only a mere start to apply
methods for glycoprotein analysis in a clinical diagnostic set-
ting. In addition, the coming decade will show a merging of
monogenic defects with genetic predisposition in more com-
mon diseases with abnormal protein glycosylation. Thus,
there is a clear need to develop additional glycoprotein bio-
markers to grasp the full scope of glycosylation defects in a
diagnostic setting, and to learn how to interpret glycosylation
abnormalities in the context of more common diseases.
Here, we will first describe the current state of diagnostics
and gene identification for CDG. Secondly, we will discuss the
potential use of existing plasma glycoprotein biomarkers, and
finish with a look to the future in suitable mass spectrometry
approaches for analysis of glycoproteins in clinical diagnostics.
CDG diagnostics and gene identification
Defects in the N-glycosylation pathway are the best studied
types of CDG. They are localized to the cytoplasm and the
endoplasmic reticulum (ER) in CDG-I or to the cytoplasm and
Golgi apparatus in CDG-II [22]. CDG-I defects are character-
ized by unoccupied glycosylation sites on proteins, thus lack-
ing complete N-glycans, whereas CDG-II defects show im-
mature, truncated glycans. Currently, the first line screening
for these CDG subgroups in the majority of metabolic labora-
tories world-wide is based on the analysis of transferrin N-
glycosylation by isoelectric focusing (TIEF), first introduced
in 1984 by Jaeken et al. [23], by HPLC [24] or by capillary
electrophoresis (CE) [25, 26]. These techniques allow separa-
tion of transferrin isoforms on basis of charge state determined
by the number of terminal sialic acid residues (see Fig. 1).
Normal plasma transferrin contains two complex type N-
glycans with in total four terminal sialic acid residues as most
dominant species (lanes 1 and 3). CDG patients show a de-
crease of this tetrasialo transferrin isoform and an increase of
lower sialylated species. Abnormal profiles are classified as
either CDG-I or CDG-II, depending on an isolated increase of
asialo- and disialotransferrin bands (lane 2, CDG-I) or an ad-
ditional increase of monosialo- and trisialotransferrin bands
(lanes 4, 5 and 6, CDG-II), respectively [27]. Diagnostic in-
terpretation of abnormal profiles can be complicated by the
presence of transferrin polymorphisms that co-migrate with
abnormally glycosylated transferrin isoforms [28, 29] (exam-
ple in lane 8, Fig. 1). Treatment of serum transferrin (in vitro)
with neuraminidase (sialidase), or alternatively analysis of pa-
rental plasma samples, is used to confirm or exclude a trans-
ferrin polymorphism [30] (lanes 6 to 9). Secondary causes of
abnormal transferrin glycosylation are for example alcohol
abuse, resulting in CDG-I profiles, the presence of sialidase
in the plasma, or severe liver disease, both resulting in CDG-II
profiles. In the majority of cases, CDG-I and -II profiles can be
clearly discriminated. However, very mild CDG-I profiles can
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be interpreted as mild CDG-II (Fig. 1, lane 6) [31], and recent-
ly a first genetic defect was reported with a mixed CDG-I/II
profile due to a combination of missing and truncated glycans
(Fig. 1, lane 7) [20].
Conventionally, the follow up in case of CDG-I profiles
consists of enzyme analysis in fibroblasts or leukocytes to di-
agnose PMM2-CDG, which is the most common type [32], or
PMI-CDG. If excluded, the next step is analysis of dolichol- or
lipid-linked oligosaccharides (LLO) in fibroblasts [33].
Nowadays, this is being replaced by whole exome sequencing
using a filter for CDG-I genes [34], or targeted sequencing of a
CDG-I gene panel. Alternatively, direct application of whole
exome sequencing without prior CDG screening increasingly
results in the identification of CDG defects, which need to be
confirmedwith Sanger sequencing. A combination of Capillary
Electrophoresis [26] or LC [19] with mass spectrometry as a
quick and sensitive test could functionally confirm the genetic
defect. Also for confirmation of mild CDG-I profiles, mixed
CDG-I/II profiles and even for further subtyping of CDG-I
defects (such as ALG1-CDG, own data), high-resolution mass
spectrometry of intact transferrin can be used.
The standard procedure for CDG-II patterns includes a fol-
low up by isoelectric focusing of plasma apolipoprotein C-III
(apoC-III-IEF) to discriminate between isolated N-
glycosylation defects and a combined disorder of N- and mu-
cin type O-glycosylation [35]. In addition, two-dimensional
electrophoresis with immunoblotting was reported to separate
and detect the isoforms of apoC-III, alpha-antitrypsin, alpha-1
acid glycoprotein, haptoglobin and transferrin [36]. Since
CDG-II is characterized by truncated glycans, mass spectrom-
etry methods can provide additional insights into the underly-
ing genetic defect. Several methods have been reported for the
analysis of transferrin glycopeptides [15, 37] and analysis of
whole serum N-glycans [16, 38, 39] by MALDI-TOF mass
spectrometry. With respect to O-glycans, mass spectrometry
analysis of apoC-III [40] and combined mass spectrometry of
released serum N- and O-glycans [41] have been reported.
Recently, mass spectrometry analysis of apoC-III O-glycosyl-
ation was compared with two-dimensional electrophoresis by
Yen-Nicolaÿ et al. and appeared to be a promising technique
for analysis of defects in mucin O-glycosylation [42].
Application of high-resolution QTOF mass spectrometry for
analysis of intact transferrin allowed to accurately annotate
glycan structures on the level of the intact protein [31, 43]
and proved highly efficient in subgrouping of CDG-II pa-
tients. For example, highly characteristic profiles can be ob-
served for MAN1B1-CDG, PGM1-CDG with a characteristic
combined CDG-I/II profile, and SLC35A2-CDG. The method
has been validated for use in a clinical metabolic laboratory.
The successful identification of gene defects directly from a
characteristic glycoprofile of transferrin, has placed this meth-
od as second test immediately following CDG screening (di-
agnostic flowchart shown in [31]).
Currently, mass spectrometry of total serum N-glycans and
of transferrin N-glycans has been included in only a few met-
abolic diagnostic laboratories. However, the high sensitivity
and high specificity have already resulted in a significant
shortening of the time to reach a genetic diagnosis in CDG,
thereby showing the advantage to use mass spectrometrymore
broadly in CDG diagnostics.
Therapy monitoring in CDG
Although many new glycosylation disorders have been iden-
tified in the last decade, only little progress has been made in
development of new therapies. Different future therapeutic
approaches have been proposed for the most common CDG
type, PMM2-CDG, in a very comprehensive review by Freeze
[44]. These include gene therapy, enzyme enhancement, en-
zyme replacement, bypassing the metabolic pathway and sub-
strate supplementation. Most of these therapeutic strategies
Fig. 1 Serum transferrin isoelectric focusing (TIEF) gels with the
number of terminal sialic acid residues indicated at the left and right
side (0 to 5). Lanes 1 and 3: normal pattern; lane 2: CDG-I pattern
(elevated asialo- and disialotransferrin bands); lanes 4, 5, 7 and 8:
CDG-II pattern (additional increase of monosialo- and trisialotransferrin
bands). Lane 6:mild CDG-I profile, resembles mild CDG-II pattern. Lane
7: combined CDG-I and -II profile. Lanes 8 to 11: transferrin before and
after neuraminidase treatment (+n) for CDG-II defect MAN1B1-CDG
and a polymorphism of transferrin, respectively. Two bands instead of
one band will become visible when treating a transferrin polymorphism
with neuraminidase
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would be applicable to other CDG types as well, but are still
under development. Several challenges have to be overcome,
like the lack of appropriate model systems, high costs, small
number of patients and the limited bioavailability of the drugs
to reach their target, especially in regard to pass the blood–
brain-barrier [44]. Only in four CDG subtypes, namely MPI-
CDG, PGM1-CDG, SLC35C1-CDG and PIGM-CDG, a
mechanism-based treatment has been applied [20, 45–48].
MPI-CDG is caused by a mutation in the cytosolic enzyme
phosphomannose isomerase (MPI). The enzyme catalyzes the
conversion of fructose-6-phosphate to mannose-6-phosphate
[49], and therefore the disease is characterized by decreased
mannose-6-phosphate. Mannose supplementation increased the
mannose-6-phosphate levels and improved the clinical features
in patients [45]. Despite mannose therapy, patients can develop
progressive liver failure at a later stage of the disease. One first
patient was successfully treated by liver transplantation, resulting
in immediate recovery ofmost severe clinical symptoms [50]. As
expected in view of the hepatic origin of transferrin, intact trans-
ferrin glycosylation profiles completely normalized after the
transplantation. However, the disease status in other organs can-
not be followed adequately by analysis of transferrin alone. This
clearly shows the need for additional biomarkers for CDG ther-
apy monitoring, including glycoproteins that are synthesized by
other tissues and cell types.
PGM1-CDG is caused by a mutation in the phosphogluco-
mutase 1 enzyme (PGM1). The enzyme catalyzes the inter-
conversion of glucose-6-phosphate and glucose-1-phosphate
[51]. The disease was identified by a highly characteristic
transferrin glycosylation profile with high-resolution mass
spectrometry, which showed a combination of CDG-I and
CDG-II. The spectra showed truncated glycans lacking galac-
tose. Based on the spectra and known metabolic pathways,
supplementation of patients with galactose resulted in almost
complete normalization of transferrin glycosylation [20]
(Fig. 2). The normalization of the truncated glycans upon
galactose treatment can be explained based on known meta-
bolic pathways. However, the normalization of the complete
glycans (CDG-I) cannot be fully explained. More detailed
insight into the dynamics and regulation of sugar metabolism,
and its link with protein glycosylation, would help us to better
understand the glycosylationmachinery, further optimize ther-
apy and develop new therapies for other CDG patients. In
addition, monitoring of the glycosylation of additional pro-
teins is required to learn if other tissues apart from liver re-
spond equally well to galactose treatment.
SLC35C1-CDG is caused by a mutation in the GDP-fucose
transporter in theGolgi-membrane, resulting in hypofucosylation
of N-glycopeptides [52]. Patients typically lack sialyl-Lewis X
(sLex) structures on the cell surface of neutrophils, which is
required for their rolling on endothelial cells before extravasation
[53]. This CDG type is therefore also known as leukocyte adhe-
sion deficiency II (LAD II) and leads to infectious complications.
Depending on the nature of the mutation, some patients respond
to L-fucose application [46, 54]. However, no proper glycopro-
tein marker is currently available to monitor therapy response
and disease progression.
PIGM-CDG is a defect in GPI-anchor biosynthesis and is
caused by a mutation in the glycosylphosphatidylinositol glycan
(classM) (PIGM) promoter. PIGM transfers the first mannose to
the GPI anchor at the luminal side of the endoplasmic reticulum
[55]. Mutation in the promoter causes histone hypoacetylation,
resulting in defective GPI anchored proteins on blood cells [47].
A patient was therefore treated with sodium phenylbutyrate,
which is a histone deacetylase inhibitor. This increased PIGM
transcription, resulting in improved GPI anchored glycopro-
teins: CD59 (MAC-inhibitory protein) on erythrocytes and
CD59 and CD24 (heat stable antigen) on granulocytes (FACS
analysis) [55]. Clinically, the patient improved and was able to
walk again and had no more seizures [48].
Currently, CDG therapy monitoring is mainly based on
clinical features, transferrin analysis or flow cytometry of sev-
eral glycoprotein surface markers on blood cells. The main
advantage of using transferrin as a biomarker for CDG is its
high abundance in blood, allowing fast, detailed and sensitive
detection of N-glycosylation in small sample volumes. Also
for treatment of fructosemia, a common secondary cause of
CDG, the loss of intact glycans can be monitored sensitively
by high resolution mass spectrometry of transferrin [31].
However, therapy monitoring in clinical diagnostics is very
limited with the analysis of transferrin, and additional bio-
markers are essential for the development and monitoring of
new and current therapies.
Novel glycoprotein biomarkers for CDG
The need for glycoprotein biomarkers beyond transferrin
Although transferrin is a very useful diagnostic biomarker for
most CDG types with deficient N-glycosylation, several de-
fects in the N-glycosylation pathway are known with a normal
transferrin profile. These include both CDG-I subtypes
(TUSC3-CDG, ALG13-CDG, ALG14-CDG), Golgi glyco-
sylation defects (GCS1-CDG, SLC35A3-CDG and
SLC35C1-CDG), as well as defects in sugar metabolism
(GNE, PGM3 and GFPT1). The growing list of these type
of defects with normal transferrin glycosylation indicates that
additional proteins have to be included for correct diagnosis.
Since glycans can be expressed in a tissue-specific way
[56–58], defects in their synthesis will be missed when ana-
lyzing only hepatocyte-derived transferrin. Furthermore, anal-
ysis of defects in the synthesis of glycan structures not or
hardly present on transferrin (such as fucose in SLC35C1-
CDG), will require inclusion of additional proteins.
Additionally, recent studies indicate the existence of
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regulatory processes in protein-specific glycosylation that we
don’t yet understand. For example, apart from the normal
glycosylation of transferrin, glycosylation of IgG was abnor-
mal in GCS1-CDG patients [59], although GCS1 is ubiqui-
tously expressed. Cohen syndrome due to mutations in
VPS13B shows normal transferrin glycosylation as well, how-
ever, Duplomb et al. found abnormal N-glycan structures by
mass spectrometry of total serum glycans [60]. They identified
a decrease in sialylation and galactosylation of total serum N-
glycans, which indicates deficient Golgi N-glycosylation of
specific proteins. They propose to analyze the highly glyco-
sylated protein intercellular cell adhesion molecule 1 (ICAM-
1) and lysosome-associated membrane protein 2 (LAMP-2) in
blood cells as a pre-screening test for Cohen syndrome.
In addition to defects in the N-glycosylation pathway, there
are many other genetic glycosylation defects (e.g., in O- and
lipid-glycosylation, and synthesis of glycosaminoglycans and
glycophosphatidylinositol (GPI) anchors) for which specific
markers need to be developed, which would be of similar
value as transferrin for defects in the N-glycosylation path-
way. In conclusion, there is a clear need for additional glyco-
protein biomarkers, in addition to transferrin, for efficient di-
agnostics of the full scope of genetic glycosylation defects.
Potential glycoprotein biomarkers for diagnostic
application in CDG
An extensive number of glycoprotein biomarkers is already de-
scribed in the literature for diagnosis of other types of diseases,
particularly for diabetes mellitus [61], Alzheimer’s disease [62],
rheumatoid arthritis or other inflammatory diseases [63, 64], and
cancer [65]. These proteins could be a potential glyco-marker for
CDG as well, because they are readily measurable in biological
matrices, and they have different type of glycosylation, or are
from other origin compared to transferrin.
The analysis of glycoprotein levels of some cancer bio-
markers is FDA approved as prognostic or diagnostic screening
[66–68], indicated by an asterisk in the table below. The detection
of most glycoproteins is still mainly based on immunoassays and
electrophoresis techniques, although the application of mass
spectrometric screening is starting to be explored as well. To
highlight the extent of today’s glycoproteomic biomarker re-
search, Table 1 provides an overview of some key examples of
candidate glycoprotein biomarkers from recent literature for the
previously mentioned diseases.
As can be seen from this overview, the number of glycopro-
teins as diagnostic biomarker is growing for multiple diseases,
see Table 1 for details and references. For some of these glyco-
proteins, altered glycosylation has already been investigated in
more detail using mass spectrometry. In particular core or sLeX
fucosylation seems to be a frequent significant change observed.
It should also be noted that the glycoprotein level is often the
diagnostic parameter. So ideally, both protein levels and glyco-
sylation analysis should be included in one assay. It could be
envisioned that combination of several plasma proteins with a
more heterogeneous glycan composition and increased
fucosylation as compared to transferrin, can be used in a panel
to further increase the diagnostic efficiency for CDG-I andCDG-
Fig. 2 Effects of Dietary
Galactose on Glycosylation. High
resolution mass spectrometry
showing glycan structures of
transferrin before (a) and after (b)
2 weeks intake of supplementary
galactose and corresponding
patterns of transferrin isoelectric
focusing (IEF). The protein
backbone is symbolized by a
brown horizontal line. The
unoccupied positions are
indicated by open arrows ( )
and define the CDG-I-component
of this phenotype. The yellow
arrow ( ) demonstrates the
absence of galactose on one of the
truncated glycans, which define
the CDG type-II component. The
number of sialic acids is indicated
above each structure, and the
insets at the right show respective
IEF results
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Table 1 Overview of some key examples of serum glycoprotein biomarkers from recent literature for diseases that present with altered glycoprotein
levels and glycosylation abnormalities
Glycoprotein Biomarker Disease Detection on protein levels or altered
glycoforms
Detection technique Reference
Transferrina – CDG – Glycosylation abnormalities – IEF, QTOF [50]
– Sepsis – Decrease in sialylation – ELLA [93]
– Acute pancreatitis – Increased fucosylation – LC-MS/MS [94]
– Ovarian cancer – Increase of concentration – ELISA [95]a
α1-antitrypsin – CDG – Altered glycosylation – 2DE [36]
– Chronic obstructive pulmonary
disease (COPD)
– Decreased concentration – ELISA [96]
– Liver cirrhosis and liver cancer – Core and outer arm fucosylation – 2DE, MALDI-TOF
– FLISA
[97]
– Lung cancer – Altered glycosylation – Lectin microarray,
ELISA
[98]
Haptoglobin – CDG – Altered glycosylation – 2DE [36]
– Long cancer – sLeX increase – HILIC, WAX-HPLC [99]
– Acute phase ovarian cancer – sLeX increase – 2DE, NP-HPLC [100]




– Pancreatic cancer – Fucosylation –MALDI-TOF
– Immunoblot
[102, 103]




– Pancreatic cancer – Changes in sialylation – LC-MS/MS [94]
– Gastric cancer – Increase of concentration – ELISA
–MRM
[105]
Fetuin – Hepatocellular carcinoma (HCC) – Fucosylation – LC-MS/MS
– FLISA
[106]
– Chronic pancreatitis, pancreatic
cancer





α-1-acid glycoprotein – CDG – Altered glycosylation – 2DE [36]
– Acute phase ovarian cancer – sLeX increase – 2DE, NP-HPLC [100]
– Chronic pancreatitis, pancreatic
cancer









Immunoglobulin G (IgG) – Acute phase ovarian cancer – sLeX increase – 2DE, NP-HPLC [100]
– Advanced ovarian cancer – Reduced galactosylation and sialylation
levels
– 2DE, NP-HPLC [100]
– Stomach cancer – Core fucosylation – 2DE, LC-MS/MS [101]
α1-antichymotrypsin – Acute phase ovarian cancer – sLeX increase – 2DE, NP-HPLC [100]
– Alzheimer’s disease – Concentration – Immunoassay [108]
α2-macroglobulin – Sjögren’s syndrome Abnormal glycosylation Immunoblot [109]
α-fetoproteina – Liver diseases – Core fucosylation, concentration – 2DE, immunoblot [110]




des-γ-carboxypro-thrombin Liver diseases, liver cancer Core fucosylation – 2DE, immunoblot [110]
Ferritin Still’s disease, hemophagocytic
syndrome
Altered glycosylation Immunoassay [111]
Ceruloplasmin – CDG – Low levels, glycosylation abnormalities – 2DE [50]
– Hepatocellular carcinoma (HCC) – Upregulated, core fucosylation – LC-MS/MS
– 2DE, MALDI-TOF
[112, 113]
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II. Apart from selections based on biological aspects as discussed
in section 4.1, an additional challenge is the mass spectrometric
compatibility and the different approaches for analysis, which
will be discussed in the next paragraph.
Mass spectrometry in glycoprotein analysis
A growing number of protein biomarkers are analyzed in the
clinics by mass spectrometry. Mass spectrometry is ideally
suited for the clinical laboratory, because the technique is sensi-
tive, compatible with biological matrices, suitable for high-
throughput analyses and it provides detailed structural informa-
tion. The technique has proven itself for CDG diagnostics
through the routine analysis of serum transferrin, which will
pave the way in the search for additional glycoprotein bio-
markers. In Fig. 3, an overview is depicted of the different levels
of glycosylation analysis by mass spectrometry, better known as
Glycomics. Intact glycoprotein analysis provides quantitative
glycan structural information of the intact glycoprotein.
Table 1 (continued)
Glycoprotein Biomarker Disease Detection on protein levels or altered
glycoforms
Detection technique Reference
– Pancreatic cancer – sLeX increase – LC-MS/MS
– Immunoblot
[114]
Thyroglobulina – CDG – Low levels, glycosylation abnormalities – 2DE [50]
– Thyroid cancer – Increase of concentration – Immunoassay [115], [68]a
Thyrotropin, Thyroid
stimulating hormone
– CDG – Low levels, altered glycosylation – IEF, serum levels [50, 116,
117]
– Thyroid function – Increase of glycoprotein concentration – Immunoassay [118]
Hemopexin Hepatocellular carcinoma (HCC) Fucosylation – LC-MS/MS
– FLISA
[106]
Clusterin – Stomach cancer – Smaller N-glycans – 2DE, LC-MS/MS [101]
– Gastric cancer – Decrease of concentration – ELISA
–MRM
[105]
– Clear cell renal cell
carcinoma








Stomach cancer Upregulation, altered glycosylation 2DE, LC-MS/MS [101, 120]
α-dystroglycan Walker-Warburg syndrome Hypoglycosylation Immunoassay [121]









Kallistatin Liver cirrhosis Increase of concentration ELISA [124]
Afamin –Metabolic syndrome – Increase of concentration – ELISA [125]
– Gastric cancer – Decrease of concentration – ELISA
–MRM
[105]





Increase of concentration Immunoassay [68], [66]a
Apolipoprotein (A-1)a Ovarian cancer Decrease of concentration ELISA [95]a
Transthyretin, prealbumina Ovarian cancer Decrease of concentration ELISA [95]a
β2-microglobulina Ovarian cancer Increase of concentration ELISA [95]a
Cancer antigen 125
(CA125) or MUC16a
Ovarian cancer Increase of concentration ELISA [67, 95]a
Carbohydrate antigen 19–9
(CA19-9)a
– Pancreatic cancer Ovarian
cancer
sLea on mucin glycoproteins ELISA [64, 68]a
Cancer antigen 15–3
(CA15-3)a
Breast cancer Sialylated O-linked oligosaccharide onMUC1 ELISA [67, 68]a
CA27-29a (MUC1) Breast cancer Protein concentration ELISA [67, 68]a
2DE 2D-electrophoresis; ELLA enzyme-linked lectin assay; FLISA Lectin-Fluorophore-linked Immunosorbent Assay; HILIC Hydrophilic Interaction
Liquid Chromatography; sLea Sialyl Lewis A structures; sLeX Sialyl Lewis X structures; WAX-HPLC weak anion exchange high performance liquid
chromatography
a FDA approved
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Quantification is possible with the assumption that ionization of
the molecules dominated by the amino acid backbone. Loss of
complete glycans can therefore accurately be detected. Intact
protein analysis is limited by size and hydrophobicity of the
protein, and limited by the number of glycosylation sites for
correct interpretation of the spectra. Glycopeptide analysis pro-
vides detailed site-specific information on glycan forms, and
enzymatic digestions increase the chance to measure large or
hydrophobic proteins of interest. However, the ionization effi-
ciency is influenced by the type of glycan, which hampers any
quantitative comparison between different glycoforms. Analysis
of free glycans allows sensitive detection of very low abundant
glycan structures, however information on the corresponding
protein/peptide attachment site is lost. Therefore, each detection
technique has its own strengths and weaknesses depending on
the intended goal of the analysis. Below, we discuss the use of
mass spectrometry in biomarker discovery and for its potential
use as a diagnostic test.
Glycoprotein biomarker discovery
The most widely used methods for biomarker discovery with-
in the field of glycomics includes free N-glycan profiling of a
biological fluid, such as serum, plasma or cerebrospinal fluid.
Many groups have published on the discovery of altered gly-
cosylation in a wide variety of diseases, and convincingly
showed that glycans have potential as biomarkers, being high-
ly sensitive to pathological changes [69–73]. Thus far, only a
very limited number of potential biomarkers based on free
glycan profiling is further developed and used in a real clinical
diagnostic test, one example being the GlycoCirrhoTest [74]
for distinguishing cirrhotic from non-cirrhotic chronic liver
disease patients.
Two major limitations of total serum N-glycan analysis
create the basis for improvement: First, the information to
which proteins glycans were attached, is lost in total serum
N-glycan analysis. Secondly, alterations in glycosylation are
biased by fluctuations in the dynamic N-glycoproteome,
which are dependent on environmental factors such as an im-
mune response [75–78]. Ideally, profiling methods need to be
used that take into account the protein to which the altered
glycans are attached, such as profiling of intact glycopeptides
from complex biological samples. Recent technical develop-
ments and improved databases seem to make this challenge
feasible. A combination of collision induced dissociation
(CID) and electron-transfer dissociation (ETD) fragmentation
techniques is preferred to characterize glycopeptides [79, 80].
While CID provides information related to the composition
and structure of glycan moieties attached to a peptide back-
bone, ETD fragments mainly the peptide backbone and leaves
the glycan intact, permitting de novo sequencing of the pep-
tide moiety [81, 82]. Due to the relative low abundance and
low ionization efficiency of glycopeptides, glycoproteins need
to be enriched, digested and chromatographically separated
for this type of analyses. Since the glycan moiety makes the
glycopeptide generally more polar, HILIC is a commonly
used enrichment strategy for glycopeptides [83]. Other usual
approaches are immune-affinity (reactive beads) [84, 85] or
lectin-affinity purifications [86, 87]. Furthermore, commercial
kits are available to deplete serum samples from the most
abundant serum proteins, although that might cause potential
biomarkers (see Table 1) to be lost. Combining these tech-
niques enables unambiguous in-depth identification of both
the peptide and the glycan. However, the data analysis soft-
ware is not yet sophisticated enough to enable automated se-
quencing of peptides and combining search results from both
fragmentation techniques for identification. Therefore, intact
glycopeptide analysis from complex biological samples is still
far from being a routine diagnostic analysis. Within a research
environment, glycopeptide profiling is highly promising for
the identification of new glycoprotein biomarkers.
One first example of glycopeptide analysis using the com-
bination of CID and ETD fragmentation, is a very recent study
of Medzihradszky et al. on tissue-specific glycosylation [58,
88]. They compared the glycosylation patterns of mouse liver
with brain tissue and not only found that these patterns differ
by the cellular location of the glycoprotein (e.g., ER, lysosom-
al or transmembrane), but also showed tissue-specific differ-
ences for the same protein.
Glycoprotein biomarker application in clinical diagnostics
Diagnostic assays are required to be fast, robust and suitable for
high-throughput measurements, while in addition the interpre-
tation in a clinical setting should be straightforward. Free N-
glycan analysis meets the technical requirements, however, di-
agnostic interpretation is highly complicated due to the many
causes that influence N-glycan profiles. For some well-defined
CDG subtypes with a clear genetic defect, such as B4GALT1-
CDG and MGAT2-CDG, interpretation is clear. However, ab-
normalities in free N-glycan profiles for other defects are more
subtle or overlapping with multiple defects. Examples include
PGM1-CDG, where the lack of complete glycans is not found
in total serum N-glycan profiles and only minimal loss of ga-
lactose is not sufficiently specific to reach a diagnosis.
Diagnostic application of glycopeptides is of particular in-
terest, because multiple identified biomarkers could subse-
quently be used for diagnostic high-throughput screening by
means of multiple/serial reaction monitoring (MRM/SRM),
similar as is increasingly used for the detection of protein
biomarkers in clinical diagnostics. In this sensitive targeted
analysis, specific (transitions of) predefined precursor ions
are sequentially selected for MS/MS detection in a quantita-
tive and reproducible manner [89]. For instance, Hong et al.
developed an MRM analysis to analyze the IgG free glycans
in whole serum. By normalizing protein glycosylation to
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absolute protein concentrations they were able to examine
quantitative changes in glycosylation at site-specific level
[90], which is crucial to distinguish between altered glycosyl-
ation and change in protein levels. Hulsmeier et al. published a
MRMmethod to quantify the N-glycosylation site occupancy
for transferrin and α1-antitrypsin, and found out that the site
occupancy correlated well with the severity of the disease
[91]. Moreover, they observed preferences for specific occu-
pation sites. The method could in principle easily be extended
to multiple glycoproteins.
Very recently, Sun et al. proposed a new method to mea-
sure absolute protein glycosylation stoichiometry in complex
biological samples [92]. They use the relative ratios between
the N-glycosylated peptide, the peptide without the glycans
and the complete glycoprotein from the same type of biolog-
ical sample to profile the glycosylation occupancy and
glycoform stoichiometry and determined 117 absolute N-
glycosylation occupancies in OVCAR-3 cells. Application
to CDG has not been tested yet, but might be promising in
biomarker discovery.
A specific set of intact glycoproteins would have several
advantages over glycopeptide mixtures, mainly improving on
the relative quantification. One needs to consider that trans-
ferrin is a relative simple glycoprotein to analyze as it has only
two glycosylation sites, whereas other proteins might go up to
multiple glycosylation sites and increased glycan heterogene-
ity. Each additional glycosylation site will complicate annota-
tion [83]. In addition, an antibody would be required to
affinity-purify the protein from the biological complex sam-
ple. The antibody would need to have its epitope outside of
any glycosylation motif, to ensure glycosylation-independent
purification of all glycoforms.
Overall, each method has its strengths and weaknesses.
Targeted, MRM based mass spectrometry of glycopeptides
is fast, robust and sensitive, allowing complex mixtures to
be analyzed. With intact glycoprotein analysis, a limited num-
ber of proteins can be analyzed. However, all glycoforms of
one protein are measured simultaneously in the mass spec-
trometer, which allows relative quantification of glycoforms
and easy comparison of both CDG type-I and CDG type-II
defects in one spectrum.
Outlook
The ultimate goal in clinical diagnostics of CDG would be to
cover the complete field of glycosylation disorders in a single
or only few assays. This would not only benefit diagnostics of
monogenic, inherited disorders of glycosylation, but also the
more common, complex genetic disorders like cancer,
Alzheimer or inflammatory diseases. Several diseases show
abnormal glycosylation, and an increasing number of glyco-
sylation disorders is identified by next generation sequencing
techniques. More and more defects within the newly discov-
ered disorders are found outside the pathway of protein N-
glycosylation, for example defects in energy metabolism, or
GPI-defects. To include these defects, the repertoire of glyco-
protein biomarkers should be expanded, by analyzing a well-
defined set of multiple, intact biomarker glycoproteins.
Fig. 3 Schematic representation
of the different types of
glycoprotein analysis using mass
spectrometry
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Table 1 provides an overview of glycoprotein biomarkers,
which are worth considering for clinical diagnostics of CDG.
It lists candidates which are already applied in clinical labora-
tories for other types of diseases, so addition of these proteins
should be feasible. Our preference is to include several pro-
teins in one assay, either as glycopeptides or as intact proteins.
The intact transferrin spectra already show the potential to
develop a unique classification system for CDG. The spectra
provide such a characteristic profile that clinical diagnostics is
possible at a glance [20, 43].
When glycoproteins are digested, housekeeping proteins or
non-glycosylated peptides of a targeted glycoprotein are nec-
essary for normalization and quantification purposes. In addi-
tion, improved ionization and enhanced separation for low
abundant glycopeptides might be required. When followed
by high-resolution detection and adequate databases for auto-
mated searches, automated MRM analyses can be used as a
fast diagnostic test. Until then, we propose that intact glyco-
protein profiling of well-defined protein mixtures will have
the best potential for CDG diagnostics and therapymonitoring
in the near future.
In conclusion, simultaneous analysis of multiple glycopro-
teins would highly increase our knowledge of the glycosyla-
tion machinery in different types of cells, and improve our
diagnostic power to sensitively and specifically monitor dis-
ease in CDG patients. A highly detailed glycosylation read-
out of individual proteins would work in synergy with Next
Generation Sequencing techniques in the identification of new
inherited disorders. Also, the diagnostics of more common
disorders shall benefit from the lessons that will be learned
from the analysis of complex glycoprotein mixtures.
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